Patents Assigned to Nymox Corporation
  • Patent number: 11628202
    Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof. Carrying out the method unexpectedly reduces the need for subsequent invasive surgical intervention.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: April 18, 2023
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 10335453
    Abstract: The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a male in need thereof.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: July 2, 2019
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 8716247
    Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 8569446
    Abstract: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: October 29, 2013
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 8293703
    Abstract: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: October 23, 2012
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 7572450
    Abstract: Disclosed is a method of preventing, inhibiting, and/or ameliorating cell death and/or tissue necrosis in live tissue by contacting live tissue with at least a segment of NTP, or homologue, variant, derivative or mimetic thereof, where the segment of NTP, or homologue, variant, derivative or mimetic thereof is present in an amount effective to prevent, inhibit, and/or ameliorate cell death and/or tissue necrosis. The method is capable of treating conditions requiring prevention, inhibition, and/or amelioration of cell death and/or tissue necrosis.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 11, 2009
    Assignee: Nymox Corporation
    Inventor: Paul A. Averback
  • Patent number: 7544771
    Abstract: Embodiments are directed to a peptide and protein containing that peptide, nucleic acids, antibodies, as well assays detecting the peptide or protein, and methods of identifying patients with or at risk of developing Alzheimer's Disease and other neurodegenerative diseases.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: June 9, 2009
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 7514407
    Abstract: The present invention relates to racemized proteins and racemized protein components of spherons that are useful for identifying compounds capable of preventing and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to the compounds identified by the methods, and methods of treating and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to methods of making an Alzheimer's Disease or dementia associated with cerebral amyloidosis animal model or test animal, the animal model produced therefrom, and to a method of using the animal model to screen for effective therapies.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: April 7, 2009
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 7270818
    Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: September 18, 2007
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 7192929
    Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: March 20, 2007
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 6942858
    Abstract: Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions containing these bacteriophages, methods of making the bacteriophage preparations and methods of treating bacterial infections using the compositions. Methods of treating bacterial infections using the compositions containing the bacteriophages in combination with conventional antibiotics also are disclosed.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 13, 2005
    Assignee: Nymox Corporation
    Inventors: Hossein A. Ghanbari, Paul Averback
  • Patent number: 6924266
    Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using peptides derived from the amino acid sequences of neural thread proteins and related molecules.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: August 2, 2005
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 6600947
    Abstract: Disclosed is a method of detecting amyloid-containing deposits in a mammal without administering exogenous chemicals such as fluorophores or chromophores. The method includes subjecting tissue of a mammal, preferably tissue of a mammal suspected of having at least one form of amyloidosis to autofluorescence-initiation, preferably by subjecting the tissue to at least excitation incident radiation from a light source having a wavelength of light within the range of from about 360 to about 370 nm, and more preferably to illumination incident radiation from a light source having wavelengths in the visible spectrum, to produce an emitted light signal beam and a reflected light signal beam. The method also preferably includes detecting the presence of emitted light having a wavelength of from about 400 nm to about 460 nm.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: July 29, 2003
    Assignee: Nymox Corporation
    Inventors: Paul A. Averback, Celine Dupuis
  • Publication number: 20030083298
    Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
    Type: Application
    Filed: July 2, 2002
    Publication date: May 1, 2003
    Applicant: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 6518314
    Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: February 11, 2003
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Hossein Ghanbari, Iraj Beheshti, David Morse
  • Patent number: 6472421
    Abstract: Described are methods for treating, preventing, or reducing the risk of the onset of Alzheimer's disease by administering a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (“HMG CoA reductase inhibitor”) to a patient who is at risk for a coronary or cerebrovascular event or at risk for Alzheimer's disease.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: October 29, 2002
    Assignee: Nymox Corporation
    Inventor: Benjamin Wolozin
  • Patent number: 6413940
    Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: July 2, 2002
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 6130221
    Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: October 10, 2000
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Hossein Ghanbari, Iraj Beheshti, David Morse